Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of
medicines that directly reprogramme the central dogma of biology to prevent and treat …

COVID-19 vaccines have been developed with unprecedented speed which would not have
been possible without decades of fundamental research on delivery nanotechnology. Lipid …

Therapeutic RNA molecules possess high potential for treating medical conditions if they
can successfully reach the target cell upon administration. However, unmodified RNA …

Hereditary genetic disorders, cancer, and infectious diseases of the liver affect millions of
people around the globe and are a major public health burden. Most contemporary …

The therapeutic potential of liposomes to deliver drugs into inflamed tissue is well
documented. Liposomes are believed to largely transport drugs into inflamed joints by …

The successful in vivo implementation of gene expression modulation strategies relies on
effective, non-immunogenic delivery vehicles. Lipid nanoparticles are one of the most …

The gastrointestinal tract (GIT) affects not only local diseases in the GIT but also various
systemic diseases. Factors that can affect the health and disease of both GIT and the human …

Lipid nanoparticles (LNPs) are currently the most promising clinical nucleic acids drug
delivery vehicles. LNPs prevent the degradation of cargo nucleic acids during blood …

Designing a therapeutic modality that will reach a certain organ, tissue, or cell type is crucial
for both the therapeutic efficiency and to limit off-target adverse effects. Nanoparticles …

The success of mRNA vaccines during the COVID-19 pandemic has greatly accelerated the
development of mRNA therapy. mRNA is a negatively charged nucleic acid that serves as a …